🔎 Trials Near Me

Home › Myelofibrosis › California

Pag-aaral pangklinika para sa Myelofibrosis sa California

21 pag-aaral para sa Myelofibrosis ang naghahanap ng mga kalahok sa mga site sa California.

Mga Lungsod sa California

Opisyal na teksto ng pag-aaral (English)

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

  • City of Hope, Duarte
  • University of Southern California, Los Angeles
  • Hoag Family Cancer Institute, Newport Beach
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT04176198

A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms

  • UCLA Ronald Reagan Medical Center, Los Angeles
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07469891

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

  • Los Angeles Cancer Network, Glendale
  • Cancer and Blood Specialty Clinic, Whittier
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07623161

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
  • UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
  • Stanford Cancer Institute Palo Alto, Palo Alto
  • at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06661915

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

  • City of Hope - Duarte, Duarte
  • City of Hope - Lennar, Irvine
  • UCLA, Los Angeles
  • at 1 pa
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT05320198

TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT

  • Stanford University, Palo Alto
Nagre-recruitPhase 1
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07302776

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  • Stanford University, Palo Alto
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07008118

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

  • City of Hope Medical Center, Duarte
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Hul 28, 2026 · NCT07020533

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

  • City of Hope-Lennar Foundation Cancer Center, Irvine
  • Usc Norris Comprehensive Cancer Center, Los Angeles
  • UCLA Medical Hematology & Oncology, Los Angeles
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 22, 2026 · NCT07441694

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

  • City of Hope Center, Duarte
  • UC Davis Comprehensive Cancer Center, Sacramento
  • UC San Diego Moores Cancer Center, San Diego
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 20, 2026 · NCT07250646

Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow

  • Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update May 4, 2026 · NCT07281781

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

  • City of Hope Medical Center, Duarte
  • Stanford Cancer Institute, Palo Alto
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 17, 2026 · NCT06034002

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

  • Los Angeles General Medical Center, Los Angeles
  • USC / Norris Comprehensive Cancer Center, Los Angeles
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 27, 2026 · NCT06063486

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

  • City of Hope Medical Center, Duarte
Nagre-recruitPhase 2Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Mar 10, 2026 · NCT06059391

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

  • University of California, Irvine, Irvine
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 10, 2026 · NCT05123365

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

  • City of Hope - Duarte Main Site, Duarte
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 12, 2026 · NCT05980806

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Duarte
  • Massive Bio SYNERGY-AI site, Irvine
  • Massive Bio SYNERGY-AI site, La Jolla
  • at 3 pa
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

  • UC San Diego Moores Cancer Center, La Jolla
  • UCLA Hematology/Oncology Clinic - Los Angeles, Los Angeles
  • Scripps Health, Prebys Cancer Center, San Diego
  • at 1 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2025 · NCT06479135

Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

  • UC Davis Health, Sacramento
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 13, 2025 · NCT05423691

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.